ReviewEffects of propofol on cancer development and chemotherapy: Potential mechanisms
Introduction
The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors (Torre et al., 2015). Despite significant advances in oncological therapies, cancer remains a major cause of morbidity and mortality. Surgical resection is the principal treatment method for most solid tumors. However, the guideline of anesthesia procedures for cancer patients is limited (Kurosawa, 2012). Growing evidence points that anesthetics influence longer-term outcome of patients after surgery, particularly cancer recurrences (Bajwa et al., 2015, Cassinello et al., 2015, Snyder and Greenberg, 2010). In order to choose the optimal anesthetics and achieve adequate anesthesia management for cancer patients, it is necessary to get a better understanding of how anesthetics affect the long-term outcome of cancer patients.(Fig. 1)
Propofol (2, 6-diisopropylphenol), one of the commonly used intravenous sedative-hypnotic agent with characteristics of smooth induction and rapid recovery from anesthesia, is extensively used for cancer resection surgery. Apart from its multiple anesthetic advantages, propofol exerts a number of non-anesthetic effects, including antitumor activity (Kushida et al., 2007, Melamed et al., 2003, Song et al., 2014, Vasileiou et al., 2009). A number of studies have indicated that propofol suppresses the malignancy of a variety of human cancers, such as hepatocellular carcinoma (HCC) (Ou et al., 2017), breast cancer (Ecimovic et al., 2014), lung cancer (Cui et al., 2014), and pancreatic cancer (Wang et al., 2015). Moreover, some studies have suggested a possible correlation between propofol and chemotherapy, though the results are undefined (Li et al., 2017, Zhang et al., 2016).
Propofol has a significant impact on process of cancer spread and chemotherapy, however, the molecular mechanisms underlying these phenomena are complex. Propofol regulates the potential malignant of cancer in direct and indirect ways. On the one hand, propofol affects key RNAs and signaling pathways directly and contributes to development of cancer. On the other hand, propofol modulates host immune function and impacts degree of immunosuppression. Therefore, this review will discuss the effect of propofol on cancer progression, including regulation of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), signaling pathways and immunity system. We also focus on the effect of propofol on chemotherapy.
Section snippets
Propofol and miRNAs
MiRNAs are a class of endogenous, single-stranded, small, non-coding RNAs that negatively regulate gene expression at the post-transcriptional level by mainly binding to 3′-untranslated region (UTR) of target mRNAs (Bartel, 2009). The role for dysregulation of miRNAs in cancer progression has been well established (Bojmar et al., 2013, Dang et al., 2017, MacDonagh et al., 2015). Propofol exerts anti-tumor potential partly due to regulating expression and transfer of miRNAs.
Indirect effect of propofol on cancer development
In addition to the effect on key moleculars and signaling pathways directly, there must be other mechanisms by which propofol contributes to cancer progression.
The cellular immune system is the critical host defence against the cancer development. Studies have shown that propofol modulated host immune function, for instance, by affecting activity of immune cells and cytokines. Propofol promotes the activity of cytotoxic T cells in mice (Kushida et al., 2007) and humans (Ren et al., 2010). In a
Effect of propofol on chemotherapy activity in vitro
Drug resistance is thought to be a major reason for the limited benefit of most cancer therapies (Hughes and Andersson, 2015, Wilting and Dannenberg, 2012). In addition to cancer development, propofol affects chemotherapeutic activity.
Conclusions
Propofol is a widely used intravenous anesthetic. In addition to its sedation/hypnotic properties, there is a casual link between propofol and cancer. However, the possible correlation between propofol and cancer is undefined. Some studies reveal that clinically relevant concentrations of propofol decreases cancer cell malignant and chemoresistance by several signaling pathways. Interestingly, opposite results indicates that propofol promotes the invasion and chemoresistance of different types
Conflicts of interest
None.
References (85)
- et al.
An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor kappab- and hypoxia-inducible factor 1alpha-mediated up-regulation of CXCR4
J. Biol. Chem.
(2013) MicroRNAs: target recognition and regulatory functions
Cell
(2009)- et al.
LncRNA HOTAIR: a master regulator of chromatin dynamics and cancer
Biochim. Biophys. Acta
(2015) - et al.
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Drug Resist. Update
(2015) - et al.
Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B
FEBS Lett.
(1998) - et al.
Cancer surgery: how may anesthesia influence outcome?
J. Clin. Anesth.
(2015) - et al.
Propofol attenuates pancreatic cancer malignant potential via inhibition of NMDA receptor
Eur. J. Pharmacol.
(2017) - et al.
Connexins, gap junctions and tissue invasion
FEBS Lett.
(2014) - et al.
Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines
Cancer Lett.
(2010) - et al.
Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations
Cancer Lett.
(2012)